PATENT CLAIM ANALYSIS

Application Number: 16249721
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "093400"]

Abstract:
Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

Claim (Index 18):
The method of  claim 13 , wherein the at least one species of gram negative bacteria comprises  Acinetobacter radioresistens, Morarella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa , or  Pseudomonas oryzihabitans.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 99.0
- Lexical Diversity: 1.32353
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16014971', '15939066', '16042939', '10575537', '10494883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7447973551773636
- 35 USC 102 Novelty (BERT): 0.5181893538481563
- Combined Prediction Score: 0.7221365550444429
- Mean Citation Score: 241.949166
- Max Citation Score: 296.65985
- Similarity Product: 196.90005164299308

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test